A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

September 27, 2024

Study Completion Date

June 30, 2027

Conditions

Lung Cancer Metastatic

Interventions

DRUG

Nivolumab

Nivolumab IV 240 mg

DRUG

Ipilimumab

Ipilimumab IV 1 mg/kg

DRUG

Evolocumab

Evolocumab 14 mg subcutaneous injection

Trial Locations (1)

Duke Univ. Medical Center, Durham

All Listed Sponsors

lead

Scott Antonia

OTHER